Components of race, ethnicity, employment play a role in opioid use disorders.
Individuals with opioid use disorder who are treated with buprenorphine, a commonly prescribed drug to treat addiction, are more likely to disengage from treatment programs if they are black or Hispanic, unemployed, or have hepatitis C according to a study published online in the Journal of Substance Abuse Treatment.
Like other chronic, life-long medical conditions such as hypertension or diabetes, opioid use disorder (OUD) requires long-term engagement in therapy for its success. According to the experts, many individuals who participate in Office Based Addiction Treatment (OBAT) with buprenorphine discontinue treatment less than one year after initiation.
To better understand the reasons for disengagement from buprenorphine treatment, researchers from Boston University Schools of Medicine (BUSM) and (BUSPH) Public Health examined patients treated at Boston Medical Center’s (BMC) OBAT program between 2002 and 2014. The observational study followed more than 1,200 patients over 12 years with the goal of identifying patient-specific factors associated with retention in the treatment program for longer than one year. It specifically evaluated age, gender, race/ethnicity, education level, employment, infection with hepatitis C virus, co-morbid psychiatric conditions, and prior or current use of drugs or alcohol.
- Physicians Treating Few Patients With Buprenorphine.
- New data show continuing opioid epidemic in the United States.
- Non-medical use of prescription opioids is associated with heroin initiation among US veterans: a prospective cohort study.
- Social, Economic, Personal-Care Factors Play Role in Readmission Risk.
While the study found that older age, female, and co-morbid psychiatric diagnosis were associated with greater odds of treatment retention beyond one year, patients who were black or Hispanic, unemployed, and had evidence of hepatitis C viral infection were associated with decreased odds of treatment retention beyond one year.
“This study highlights some important disparities in treatment outcomes, especially racial/ethnic disparities in outcomes, which reflect a larger issue in medical care in general as well as in society at large,” explained lead author Zoe Weinstein, MD, assistant professor of medicine at BUSM and director of the Addiction Consult Service at BMC. She points out that identifying risk factors for disengagement is especially important given the increased focus from researchers and clinicians to expand access to treatment with opioid agonist, such as buprenorphine, in light of the current opioid epidemic.